RemeGen Co., Ltd. (9995.HK)
HKD 41.4
(8.8%)
HKD 41.4
(8.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.24 Billion CNY | -54.16% |
| 2022 | -805.7 Million CNY | -300.47% |
| 2021 | 402.05 Million CNY | 168.1% |
| 2020 | -661.56 Million CNY | -71.84% |
| 2019 | -343.85 Million CNY | -64.75% |
| 2018 | -208.71 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -369.06 Million CNY | -26.43% |
| 2024 Q1 | -291.9 Million CNY | 34.54% |
| 2023 Q3 | -315.44 Million CNY | 11.74% |
| 2023 FY | - CNY | -54.16% |
| 2023 Q4 | -445.93 Million CNY | -41.37% |
| 2023 Q2 | -357.37 Million CNY | -18.72% |
| 2023 Q1 | -301.03 Million CNY | 1.56% |
| 2022 Q3 | -205.89 Million CNY | -4.27% |
| 2022 Q1 | -274.45 Million CNY | -133.03% |
| 2022 Q2 | -197.46 Million CNY | 28.05% |
| 2022 FY | - CNY | -300.47% |
| 2022 Q4 | -305.81 Million CNY | -48.52% |
| 2021 Q3 | -212.03 Million CNY | 16.98% |
| 2021 Q1 | -185.03 Million CNY | 14.32% |
| 2021 FY | - CNY | 168.1% |
| 2021 Q2 | -255.39 Million CNY | -38.02% |
| 2021 Q4 | 830.89 Million CNY | 491.87% |
| 2020 Q3 | -215.96 Million CNY | -50.42% |
| 2020 Q4 | -215.96 Million CNY | 0.0% |
| 2020 Q2 | -143.57 Million CNY | -66.84% |
| 2020 Q1 | -86.05 Million CNY | 21.22% |
| 2020 FY | - CNY | -71.84% |
| 2019 Q1 | -68.51 Million CNY | 20.26% |
| 2019 FY | - CNY | -64.75% |
| 2019 Q4 | -109.23 Million CNY | 0.0% |
| 2019 Q3 | -109.23 Million CNY | -12.87% |
| 2019 Q2 | -96.77 Million CNY | -41.25% |
| 2018 Q4 | -85.92 Million CNY | 0.0% |
| 2018 Q2 | -51.81 Million CNY | 0.0% |
| 2018 Q1 | -51.81 Million CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2017 Q4 | -51.81 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 1467.757% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 356.341% |